Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment reporting

Analytics

Phase 1/2
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1/2(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07877610Phase 1/2Recruiting

CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

Role: lead

NCT05869279Phase 1/2Recruiting

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

Role: lead

SYF994b4ea311e34c589834599f67bd68d8Phase 2Unknown

Therapeutic strategy driven by residual disease for CARCIK-CD19 in patients with relapsed/refractory B cell precursor Acute Lymphoblastic Leukemia

Role: lead

All 3 trials loaded